TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a report issued on Wednesday,Benzinga reports. They currently have a $11.00 price target on the stock.

A number of other equities research analysts have also commented on TCRX. Wedbush restated an “outperform” rating and set a $10.00 price objective on shares of TScan Therapeutics in a report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, TScan Therapeutics currently has an average rating of “Buy” and a consensus target price of $12.00.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock opened at $5.78 on Wednesday. The stock’s fifty day simple moving average is $5.35 and its 200 day simple moving average is $6.56. The company has a current ratio of 7.77, a quick ratio of 7.77 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $306.17 million, a PE ratio of -5.50 and a beta of 0.79. TScan Therapeutics has a 12 month low of $3.73 and a 12 month high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. TScan Therapeutics had a negative return on equity of 59.83% and a negative net margin of 855.84%. The company had revenue of $0.54 million for the quarter, compared to analyst estimates of $1.55 million. On average, research analysts predict that TScan Therapeutics will post -1.17 EPS for the current year.

Insider Transactions at TScan Therapeutics

In related news, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the sale, the insider now owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Barbara Klencke bought 5,000 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The stock was acquired at an average cost of $5.29 per share, with a total value of $26,450.00. Following the completion of the purchase, the director now owns 45,000 shares of the company’s stock, valued at $238,050. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Zoran Zdraveski sold 164,686 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the sale, the insider now directly owns 4,716 shares in the company, valued at $27,258.48. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders acquired a total of 15,000 shares of company stock worth $82,550 in the last three months. Insiders own 2.76% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TCRX. Dimensional Fund Advisors LP acquired a new stake in TScan Therapeutics in the 2nd quarter valued at about $70,000. SG Americas Securities LLC bought a new stake in TScan Therapeutics in the third quarter valued at approximately $78,000. The Manufacturers Life Insurance Company acquired a new stake in shares of TScan Therapeutics in the second quarter valued at approximately $90,000. Cornercap Investment Counsel Inc. bought a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $134,000. Finally, Rhumbline Advisers acquired a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $274,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.